Emergency Briefing: “The Great Reset”
By May 28th, Americans could be faced with a difficult choice: Accept a "Great Reset" and risk losing the American way of life... or stand up and fight back to save what's left of the American dream. Jeff Brown, a member of a D.C.-based advocacy group, explains what every American must do before May 28th to preserve his assets and thrive.
Click here to see this emergency briefing before i
Kevin R. Sayer, insider at DexCom

Kevin R. Sayer Insider Information

CEO of DexCom

Kevin Sayer is the president, chairman, and CEO of Dexcom, a company that develops, manufactures, and distributes continuous glucose monitoring systems.

Sayer joined Dexcom as its president and chief operating officer in 2011, and he became CEO in 2015. In his various roles, he has directed research and development, manufacturing, regulatory, clinical, finance, marketing, and sales functions.

He has played a leading role in developing new technologies in the United States and Europe, including the Dexcom G5 Mobile CGM System and the Dexcom G4 PLATINUM System with Share, among others.

Before joining Dexcom, Sayer was the chief financial officer for medical technology company, Biosensors International. He has also served as an independent healthcare and medical technology industry consultant, as the executive vice president and CFO for Specialty Laboratories, and as the CFO of MiniMed from 1994 until 2001, when it was acquired by Medtronic. 

Sayer was recognized on Forbes’ “Innovative Leaders” list in 2019.

He earned both his B.S. and M.S. in accounting and information systems at Brigham Young University.

Within the last three months, Kevin R.. Sayer has sold $2,281,054.00 in shares of DexCom stock. Most recently, Kevin R. Sayer sold 6,221 shares of the business's stock in a transaction on Monday, April 5th. The shares were sold at an average price of $366.67, for a transaction totalling $2,281,054.07.

Read More

Kevin R. Sayer Insider Trading History at DexCom

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/5/2021Sell6,221$366.67$2,281,054.07  
3/9/2021Sell3,857$361.11$1,392,801.27  
2/1/2021Sell12,468$378.17$4,715,023.56  
1/12/2021Sell39,949$362.09$14,465,133.41  
12/1/2020Sell13,233$322.18$4,263,407.94  
10/29/2020Sell13,830$340.14$4,704,136.20  
9/9/2020Sell9,965$398.30$3,969,059.50  
7/6/2020Sell6,000$420.94$2,525,640.00  
6/1/2020Sell6,000$376.57$2,259,420.00  
5/4/2020Sell6,000$344.63$2,067,780.00  
4/7/2020Sell6,000$262.81$1,576,860.00  
3/11/2020Sell20,374$264.82$5,395,442.68  
3/9/2020Sell6,000$269.02$1,614,120.00  
2/10/2020Sell6,000$242.39$1,454,340.00  
1/13/2020Sell6,000$230.62$1,383,720.00  
12/2/2019Sell10,000$221.37$2,213,700.00  
11/4/2019Sell10,000$157.50$1,575,000.00  
10/1/2019Sell10,000$149.60$1,496,000.00  
9/9/2019Sell14,322$149.86$2,146,294.92  
9/3/2019Sell10,000$170.13$1,701,300.00  
8/15/2019Sell10,000$156.12$1,561,200.00  
7/8/2019Sell6,000$146.25$877,500.00  
6/10/2019Sell6,000$132.74$796,440.00  
5/13/2019Sell6,000$115.73$694,380.00  
4/15/2019Sell6,000$118.91$713,460.00  
3/12/2019Sell32,566$142.83$4,651,401.78  
2/11/2019Sell6,000$148.90$893,400.00  
1/14/2019Sell6,000$140.99$845,940.00  
12/10/2018Sell11,162$121.67$1,358,080.54  
11/12/2018Sell11,161$146.43$1,634,305.23  
10/8/2018Sell11,161$124.76$1,392,446.36  
9/10/2018Sell25,495$143.62$3,661,591.90  
8/13/2018Sell11,161$123.22$1,375,258.42  
7/9/2018Sell14,219$99.79$1,418,914.01  
12/12/2017Sell6,000$58.85$353,100.00  
11/20/2017Sell12,000$55.00$660,000.00  
9/20/2017Sell6,000$69.34$416,040.00  
8/11/2017Sell6,000$69.77$418,620.00  
7/12/2017Sell6,000$71.86$431,160.00  
6/12/2017Sell6,000$69.07$414,420.00  
10/14/2016Sell7,000$81.87$573,090.00  
9/14/2016Sell7,000$91.79$642,530.00  
8/15/2016Sell7,000$90.78$635,460.00  
7/13/2016Sell7,000$79.92$559,440.00  
6/20/2016Sell35,000$75.00$2,625,000.00  
See Full Table

Kevin R. Sayer Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $382.89
$373.10
$383.17

50 Day Range

MA: $370.65
$339.15
$418.94

52 Week Range

Now: $382.89
$270.11
$456.23

Volume

431,350 shs

Average Volume

853,048 shs

Market Capitalization

$36.83 billion

P/E Ratio

158.22

Dividend Yield

N/A

Beta

0.86
Breaking Now: Biden's Disturbing Plan to "Reset" America
The “Great Reset” started on January 20th with the inauguration of Joe Biden. Between now and the midterms, the American economy could be reshaped forever – and renowned analyst Jeff Brown has found the “lynchpin” to the entire plan.
Go here before this message is removed.